Search our Database of Scientific Publications and Authors

I’m looking for a

    3342 results match your criteria Plaque Psoriasis

    1 OF 67

    The GENDER ATTENTION Observational Study: Gender and Hormonal Status Differences in the Incidence of Adverse Events During Cyclosporine Treatment in Psoriatic Patients.
    Adv Ther 2017 Apr 21. Epub 2017 Apr 21.
    UCB Pharma Italia, Milan, Italy.
    Introduction: Female sex has been shown to be a risk factor for the development of adverse drug reactions; however, this has not been studied for cyclosporine (CsA). The aim of this study was to investigate, in Italian dermatological practice, the influence of gender and menopause and related hormones on the incidence of adverse events (AEs) during CsA treatment in psoriatic patients.

    Methods: Multicenter, prospective, observational study conducted from May 2011 to June 2013. Read More

    Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
    N Engl J Med 2017 04;376(16):1551-1560
    From K. Papp Clinical Research and Probity Medical Research, Waterloo, ON (K.A.P.), School of Medicine, Queen's University, Kingston, ON (M.G.), and Centre for Dermatology and Probity Medical Research, Peterborough, ON (M.G.) - all in Canada; Oregon Medical Research Center, Portland (A.B.); Altman Dermatology Associates, Arlington Heights, IL (M.B.); Rockefeller University, New York (J.K.); Hôpital de l'Archet, University of Nice-Sophia Antipolis, Nice, France (J.-P.L.); Baylor Research Institute, Dallas (A.M.); Charité Universitätsmedizin Berlin, Berlin (S.P.), Boehringer Ingelheim Pharma, Biberach (B.R.B.), and Boehringer Ingelheim Pharma, Ingelheim, (S.J.P.) - all in Germany; University of Texas Health Science Center, Houston (S.T.); University of California, Los Angeles, School of Medicine, Los Angeles (H.S.); and Boehringer Ingelheim Pharmaceuticals, Ridgefield, CT (S.V., C.P., N.B., M.F., P.S.).
    Background Interleukin-23 is thought to be critical to the pathogenesis of psoriasis. We compared risankizumab (BI 655066), a humanized IgG1 monoclonal antibody that inhibits interleukin-23 by specifically targeting the p19 subunit and thus prevents interleukin-23 signaling, and ustekinumab, an interleukin-12 and interleukin-23 inhibitor, in patients with moderate-to-severe plaque psoriasis. Methods We randomly assigned a total of 166 patients to receive subcutaneous injections of risankizumab (a single 18-mg dose at week 0 or 90-mg or 180-mg doses at weeks 0, 4, and 16) or ustekinumab (45 or 90 mg, according to body weight, at weeks 0, 4, and 16). Read More

    Expression of low-density lipoprotein related receptors 5 and 6 (LRP5/6) in psoriasis skin.
    Exp Dermatol 2017 Apr 18. Epub 2017 Apr 18.
    Division of Dermatology and Venereology, Region Jönköping County, Jönköping, Sweden.
    Low-density lipoprotein-related receptors 5 and 6 (LRP5/6) are transmembrane receptors with key functions in canonical Wnt signaling. Wnt ligands are thought to play an important role in innate immunity and psoriasis and recent studies assigned LRP5/6 anti-inflammatory properties. The objective of this study was to investigate the expression of LRP5 and LRP6 in lesional and non-lesional skin in peripheral blood and in mononuclear cells of patients with chronic plaque type psoriasis compared with control individuals. Read More

    Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2).
    J Am Acad Dermatol 2017 Apr 14. Epub 2017 Apr 14.
    Modern Research Associates, Dallas, Texas.
    Background: Randomized, controlled trials demonstrated efficacy and safety of apremilast for moderate-to-severe plaque psoriasis and psoriatic arthritis.

    Objective: Assess long-term safety of oral apremilast in psoriasis patients.

    Methods: Safety findings are reported for 0 to ≥156 weeks from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2. Read More

    Comparison of Occlusive and Open Application in a Psoriasis Plaque Test Design, Examplarily Using Investigations of Mapracorat 0.1% Ointment versus Vehicle and Reference Drugs.
    Skin Pharmacol Physiol 2017 Apr 14;30(2):102-114. Epub 2017 Apr 14.
    bioskin GmbH, Hamburg, Germany.
    Background/aims: Psoriasis plaque tests (PPTs) are important tools in the early phases of antipsoriatic drug development. Two distinct PPT design variants (open vs. occluded drug application) are commonly used, but no previous work has aimed to directly compare and contrast their performance. Read More

    Secukinumab - First in Class Interleukin-17A Inhibitor for the Treatment of Psoriasis.
    Indian J Dermatol 2017 Mar-Apr;62(2):195-199
    Department of Dermatology, D Y Patil University School of Medicine, Navi Mumbai, Maharashtra, India.
    Psoriasis is a complex inflammatory disease that occurs in genetically susceptible individuals and presents with the development of erythematous scaly plaques on the skin. Interleukins (ILs) in the Th17 pathway play a pivotal role in the pathogenesis of psoriasis and have thus become targets for recent biologic drug development. Secukinumab is a human monoclonal IgG1k antibody that has been developed to target and block the actions of IL-17A. Read More

    Efficacy and safety of total glucosides of paeony combined with acitretin in the treatment of moderate-to-severe plaque psoriasis: a double-blind, randomised, placebo-controlled trial.
    Eur J Dermatol 2017 Apr;27(2):150-154
    Department of Dermatology, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
    Although acitretin has been widely used for the treatment of psoriasis, additional safer and more effective approaches, including traditional Chinese medicine, are needed. To investigate the efficacy and safety of total glucosides of paeony (TGP) combined with acitretin in the treatment of moderate-to-severe plaque psoriasis. A randomised, double-blind, placebo-controlled, multi-centre clinical study was conducted. Read More

    Misdiagnosed crusted scabies in an AIDS patient leads to hyperinfestation.
    Cutis 2017 Mar;99(3):202-204
    University of Texas Medical Branch, Galveston, USA.
    Crusted scabies is a severe, highly contagious form of classic scabies caused by the mite Sarcoptes scabiei var hominis. Crusted scabies is more common in immunosuppressed populations and overcrowded environments. In this condition, the host's immune system is overwhelmed and unable to defend against the mites on the skin, resulting in hyperinfestation of the host. Read More

    Secukinumab is Efficacious and Safe in Hispanic Patients with Moderate-to-Severe Plaque Psoriasis: Pooled Analysis of Four Phase 3 Trials.
    Adv Ther 2017 Apr 10. Epub 2017 Apr 10.
    Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.
    Introduction: There is little evidence available on the efficacy and safety of biologic therapies for the treatment of psoriasis in Hispanic patients. Secukinumab is demonstrated to be highly effective for clearing psoriasis. The aim of this study was to compare the efficacy and safety of secukinumab in Hispanic and non-Hispanic patients. Read More

    Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis.
    J Am Acad Dermatol 2017 Apr 7. Epub 2017 Apr 7.
    Pfizer Inc, Collegeville, Pennsylvania. Electronic address:
    Background: Tofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated.

    Objective: We sought to assess the efficacy of tofacitinib for the treatment of nail psoriasis over a period of 52 weeks. Read More

    Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis: Efficacy, safety and tolerability results from a phase 2b randomized controlled trial.
    J Dermatol 2017 Apr 9. Epub 2017 Apr 9.
    Kojinkai Sapporo Skin Clinic, Sapporo, Japan.
    Apremilast, an oral, small-molecule phosphodiesterase 4 inhibitor, works intracellularly within immune cells to regulate inflammatory mediators. This phase 2b randomized, placebo-controlled study evaluated efficacy and safety of apremilast among Japanese patients with moderate to severe plaque psoriasis. In total, 254 patients were randomized to placebo, apremilast 20 mg b. Read More

    The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies.
    J Allergy Clin Immunol 2017 Apr;139(4S):S65-S76
    Department of Pediatrics, National Jewish Health, Denver, Colo. Electronic address:
    Atopic dermatitis (AD), the most common chronic inflammatory skin disease, is driven by both terminal keratinocyte differentiation defects and strong type 2 immune responses. In contrast to chronic plaque-type psoriasis, AD is now understood to be a much more heterogeneous disease, with additional activation of TH22, TH17/IL-23, and TH1 cytokine pathways depending on the subtype of the disease. In this review we discuss our current understanding of the AD immune map in both patients with early-onset and those with chronic disease. Read More

    Nail psoriasis - what a rheumatologist should know about.
    Reumatologia 2017 22;55(1):44-47. Epub 2017 Mar 22.
    Chair and Department of Hygiene, Medical University of Lublin, Poland.
    Psoriasis is a chronic recurrent inflammatory skin disease with prevalence of 1-3%. Nail psoriasis affects 10-90% of patients with plaque psoriasis. The aim of the article is to review the literature for the correlation between nail psoriasis and psoriatic arthritis (PsA) to provide rheumatologists a short review on features of nail psoriasis, methods of their assessment and possible clinical repercussions. Read More

    Metabolic Syndrome in Psoriasis among Urban South Indians: A Case Control Study Using SAM-NCEP Criteria.
    J Clin Diagn Res 2017 Feb 1;11(2):WC01-WC04. Epub 2017 Feb 1.
    Junior Resident, Department of Dermatology, K.S Hegde Medical Academy , Mangalore, Karnataka, India .
    Introduction: Psoriasis is a chronic inflammatory disease of the skin associated with increased cardiovascular morbidity. Metabolic syndrome is a significant forecaster of cardiovascular events.

    Aim: To assess the association of metabolic syndrome and its components in patients with psoriasis and to compare it with the age and sex matched control group. Read More

    The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.
    Mol Diagn Ther 2017 Apr 3. Epub 2017 Apr 3.
    Department of Dermatology, University of Rome Tor Vergata, Viale Oxford, 81-00133, Rome, Italy.
    Psoriasis is a chronic inflammatory disease triggered by both genetic and environmental factors. Systemic and biologic therapies used to treat moderate-to-severe psoriasis show significant variability in efficacy, are associated with various degrees of toxicity, and, for biologic therapies, are expensive. There is a great need for non-invasive biomarkers to predict treatment outcomes of these therapies and to individualize care for patients with psoriasis. Read More

    The Effect of Body Weight on the Efficacy and Safety of Ixekizumab: Results from an Integrated Database of 3 Randomized, Controlled Phase 3 Studies of Patients with Moderate-to-Severe Plaque Psoriasis.
    J Eur Acad Dermatol Venereol 2017 Apr 1. Epub 2017 Apr 1.
    St. Louis University School of Medicine, St. Louis, MO, USA.
    Background: There is concern that increased body weight may impact efficacy of some therapies used to treat psoriasis.

    Objective: To evaluate the effect of body weight on response to ixekizumab treatment in moderate-to-severe psoriasis patients.

    Methods: Patients were characterized under 3 body weight categories (<80 kg, 80 to 100 kg, ≥100 kg) in this preplanned subgroup analysis from an integrated database of 3 multicenter, randomized, double-blind, controlled Phase 3 clinical studies (UNCOVER -1, UNCOVER-2, and UNCOVER-3). Read More

    Effectiveness of adalimumab in the treatment of scalp and nail affection in patients with moderate to severe plaque psoriasis in routine clinical practice.
    Acta Dermatovenerol Alp Pannonica Adriat 2017 Mar;26(1):11-14
    Global Medical Affairs Immunology, AbbVie, Ljubljana, Slovenia.
    Introduction: Data on the effectiveness of biologics in the treatment of nail and scalp psoriasis (PSO) in a routine clinical setting are scarce. The aim of this study was therefore to evaluate the effectiveness of adalimumab in the treatment of nail and scalp psoriatic lesions in routine dermatologic practice.

    Methods: Five hundred one patients were analyzed in this observational study; 157 patients had nail involvement (nail PSO set; NPS) and 404 had scalp involvement (scalp PSO set; SPS). Read More

    Role of IL-17 in plaque psoriasis: therapeutic potential of ixekizumab.
    Ther Clin Risk Manag 2017 13;13:315-323. Epub 2017 Mar 13.
    Centre for Dermatology; Centre for Pharmacoepidemiology and Drug Safety, Manchester Academic Health Science Centre, Manchester, UK.
    Developments in the understanding of the immunopathogenesis of psoriasis have identified interleukin (IL)-17 as the key proinflammatory cytokine in the pathogenesis of plaque psoriasis, with the consequent development of drugs that target this cytokine or associated receptors. Ixekizumab is a subcutaneously administered humanized monoclonal antibody, which acts to neutralize IL-17A. This article reviews the role of IL-17 in the pathogenesis of psoriasis, the biological and pharmacokinetics of ixekizumab and the safety profile and the clinical efficacy of ixekizumab in Phase III clinical trials. Read More

    Severity of Psoriasis Differs Between Men and Women: A Study of the Clinical Outcome Measure Psoriasis Area and Severity Index (PASI) in 5438 Swedish Register Patients.
    Am J Clin Dermatol 2017 Mar 24. Epub 2017 Mar 24.
    Dermatology, Department of Public Health and Clinical Medicine, Umea University, 901 85, Umeå, Sweden.
    Background: Psoriasis is a common skin disease and moderate to severe psoriasis is associated with a dose-dependent risk for metabolic and cardiovascular morbidity. It has previously been speculated that women have less severe psoriasis, as men are overrepresented in psoriasis registers and consume more care.

    Objective: The objective of this study was to investigate, for the first time, the sex differences in the severity of psoriasis using the gold standard of severity measurement, the Psoriasis Area and Severity Index (PASI), and the distinct elements of the PASI score. Read More

    A Review of Guselkumab, an IL-23 Inhibitor, for Moderate-to-Severe Plaque Psoriasis.
    Skin Therapy Lett 2017 Mar;22(2):8-10
    Department of Dermatology, University of Texas Health Science Center, Houston, TX, USA.
    Psoriasis is a chronic inflammatory skin disorder that affects 2% of the population. Evidence suggests that interleukin (IL)-23 plays a pivotal role in the pathogenesis of psoriasis. Guselkumab is a subcutaneously administered, humanized anti-IL23 monoclonal antibody indicated for the treatment of moderate-to-severe plaque psoriasis. Read More

    Tofacitinib in the Treatment of Rheumatoid Arthritis and Chronic Plaque Psoriasis.
    Skin Therapy Lett 2017 Mar;22(2):1-7
    University of Toronto Department of Medicine, Toronto, ON, Canada; Lynde Institute for Dermatology, Markham, ON, Canada.
    Tofacitinib is an oral immunosuppressant approved for the treatment of rheumatoid arthritis (RA) and is currently undergoing investigation (Phase III trials) for treating chronic plaque psoriasis. Tofacitinib inhibits Janus kinases (JAKs), which are essential for the signaling of multiple inflammatory pathways and have been implicated in the pathogenesis of RA and psoriasis. The efficacy and safety of tofacitinib in the treatment of RA and psoriasis have been demonstrated in Phase III trials. Read More

    Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate to severe plaque psoriasis and non-pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER-1, -2, and -3).
    J Eur Acad Dermatol Venereol 2017 Mar 21. Epub 2017 Mar 21.
    Dermatologikum Hamburg and SCIderm GmbH, Hamburg, Germany.
    Background: Palmoplantar psoriasis has significant physical and emotional impact on patients and can be difficult to treat.

    Objective: To evaluate the efficacy of ixekizumab in the treatment of patients with moderate-to-severe non-pustular palmoplantar involvement and moderate-to-severe plaque psoriasis.

    Methods: In three phase 3, double-blind, placebo-controlled trials, patients with moderate-to-severe non-pustular plaque psoriasis (UNCOVER-1 (N=1296), UNCOVER-2 (N=1224), UNCOVER-3 (N=1346)) were randomised to subcutaneous 80 mg ixekizumab every 2 or 4 weeks (Q2W, Q4W), after a 160 mg starting dose, or placebo through week 12. Read More

    Biosimilars in psoriasis: the future or not?
    Cutis 2017 Feb;99(2):116-120
    Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
    As patents for the biologic agents reach their expiration dates, dermatologists must prepare for the coming of biosimilars. These agents have been deemed "highly similar" to their reference products in a process outlined by the US Food and Drug Administration (FDA). In 2016, the FDA approved 3 biosimilars for various indications including plaque psoriasis and psoriatic arthritis. Read More

    Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body Weight.
    CPT Pharmacometrics Syst Pharmacol 2017 Mar 20. Epub 2017 Mar 20.
    Pfizer Inc, Groton, Connecticut, USA.
    Tofacitinib is an oral Janus kinase inhibitor. An integrated analysis was conducted to evaluate dosage optimality for tofacitinib in patients with moderate-to-severe plaque psoriasis and the impact of body weight on optimality in this patient population. Data were pooled from one phase IIb trial (2, 5, and 15 mg twice daily (b. Read More

    Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Enhanced Lotion Formulation of Halobetasol Propionate, 0.05% Versus Its Vehicle in Adult Subjects With Plaque Psoriasis.
    J Drugs Dermatol 2017 Mar;16(3):234-240

    BACKGROUND: A novel lotion formulation of halobetasol propionate, 0.05% (HBP Lotion) with enhanced vehicle characteristics of a cream while preserving the ease of use and cosmetic elegance of a lotion has been developed to treat plaque psoriasis.

    Objective: Determine the safety and effectiveness of HBP Lotion in patients with plaque psoriasis. Read More


    Patient Preference for Dosing Frequency Based on Prior Biologic Experience.
    J Drugs Dermatol 2017 Mar;16(3):220-226
    Background: There is limited research exploring patient preferences regarding dosing frequency of biologic treatment of psoriasis.

    Methods: Patients with moderate-to-severe plaque psoriasis identified in a healthcare claims database completed a survey regarding experience with psoriasis treatments and preferred dosing frequency. Survey questions regarding preferences were posed in two ways: (1) by likelihood of choosing once per week or 2 weeks, or 12 weeks; and (2) by choosing one option among once every 1-2 or 3-4 weeks or 1-2 or 2-3 months. Read More

    A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    J Drugs Dermatol 2017 Mar;16(3):197-204

    BACKGROUND: Psoriasis is a chronic, immune-mediated disease that varies widely in its clinical expression. Treatment options focus on relieving symptoms, reducing inflammation, induration, and scaling, and controlling the extent of the disease. Topical corticosteroids are the mainstay of treatment, however long-term safety remains a concern, particularly with the more potent formulations. Read More


    Porokeratosis ptychotropica.
    An Bras Dermatol 2016 Sep-Oct;91(5 suppl 1):134-136
    Universidade de Santo Amaro (UNISA) - Santo Amaro (SP), Brazil.
    Porokeratosis is a skin disorder clinically characterized by annular plaques with keratotic borders resembling the Great Wall of China and histopathologically by cornoid lamellae. The disease has several clinical variants. Porokeratosis ptychotropica, which has recently become part of these variants, is quite rare and little known. Read More

    Interleukin (IL)-18, cooperatively with IL-23, induces prominent inflammation and enhances psoriasis-like epidermal hyperplasia.
    Arch Dermatol Res 2017 May 15;309(4):315-321. Epub 2017 Mar 15.
    Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe, 650-0017, Japan.
    The interleukin (IL)-23/IL-17 axis is strongly implicated in the pathogenesis of psoriasis. Previous studies showed that IL-18 was elevated in early active and progressive plaque-type psoriatic lesions and that serum or plasma levels of IL-18 correlated with the Psoriasis Area and Severity Index. However, the mechanism whereby IL-18 affects disease severity remains unknown. Read More

    Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study.
    J Am Acad Dermatol 2017 Mar 10. Epub 2017 Mar 10.
    Probity Medical Research, Farmington, Australia; University of Connecticut Health Center, Connecticut.
    Background: ABP 501 is a biosimilar of adalimumab.

    Objective: We sought to compare the efficacy and safety of ABP 501 with adalimumab.

    Methods: This 52-week, double-blind study randomized patients with moderate to severe psoriasis to ABP 501 or adalimumab. Read More

    Orbital Cellulitis in a Psoriatic Patient Treated With Adalimumab.
    Mil Med 2017 Mar;182(3):e1880-e1882
    Department of Dermatology, Naval Health Clinic Hawaii, 480 Central Avenue, Pearl Harbor, HI 96869.
    Introduction: Psoriatic patients on tumor necrosis factor alpha inhibitors (TNFi) may be at increased risk for upper respiratory tract infections, including chronic rhino-sinusitis (CRS). Rarely, CRS can progress to orbital cellulitis (OC), an emergent ophthalmic complication wherein respiratory flora from paranasal sinus disease intrude the retro-orbital space.

    Materials And Methods: Single case report. Read More

    Establishment of the first WHO International Standard for etanercept, a TNF receptor II Fc fusion protein: Report of an international collaborative study.
    J Immunol Methods 2017 Mar 10. Epub 2017 Mar 10.
    European Directorate for the Quality of Medicines & HealthCare, 7 allée Kastner, CS 30026, F-67081 Strasbourg, France.
    Etanercept, a recombinant human tumor necrosis factor (TNF) receptor Fc fusion protein is an effective treatment option in adults with rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis or plaque psoriasis and paediatrics with juvenile idiotypic arthritis and plaque psoriasis. Patent expiration in Europe and intense development of various etanercept products worldwide triggered a need for an international reference standard to facilitate determination of biological activity. Therefore, three candidate preparations of etanercept were lyophilized and evaluated in a multi-centre collaborative study comprising twenty eight laboratories from 15 countries for their suitability to serve as an international standard for the bioactivity of TNF receptor II Fc fusion proteins (international nonproprietary name, Etanercept). Read More

    Differentiation of pityriasis rubra pilaris from plaque psoriasis by dermoscopy.
    Arch Dermatol Res 2017 May 9;309(4):311-314. Epub 2017 Mar 9.
    Department of Dermatology, Venereology and Andrology, Faculty of Medicine, Assiut University, Assiut, Egypt.
    Pityriasis rubra pilaris (PRP) and plaque psoriasis (PP) are two distinctive erythemato-squamous skin diseases that often have to be differentiated from each other and from other similar dermatoses. Dermoscopy has been proven to aid the clinical diagnosis of several inflammatory disorders, minimizing the need for skin biopsy. Our aim was to determine the dermoscopic patterns of PRP compared to PP and to assess the significance of certain dermoscopic criteria in the diagnosis of PRP. Read More

    Evaluation of psoriasis patients' attitudes toward benefit-risk and therapeutic trade-offs in their choice of treatments.
    Patient Prefer Adherence 2017 28;11:353-362. Epub 2017 Feb 28.
    Clinical Outcomes Assessment, ICON Clinical Research UK Ltd.
    Objective: Treatment options for psoriasis offer trade-offs in terms of efficacy, convenience, and risk of adverse events. We evaluated patients' preferences with respect to benefit-risk in the treatment of psoriasis.

    Methods: A discrete choice experiment was conducted in adults from the UK with moderate-to-severe psoriasis using an orthogonal design with 32 hypothetical choice sets. Read More

    Apremilast for the management of moderate to severe plaque psoriasis.
    Expert Rev Clin Pharmacol 2017 Apr 17;10(4):349-360. Epub 2017 Feb 17.
    b Department of Dermatology , University of Cincinnati Medical Center , Cincinnati , OH , USA.
    Introduction: Psoriasis is a chronic inflammatory skin disease characterized by erythematous plaques on extensor surfaces, scalp, and back. Current therapies for psoriasis are limited by route of administration, side effects, and cost. Apremilast is the first oral phosphodiesterase inhibitor approved for moderate-to-severe plaque psoriasis. Read More

    Impact of immunogenicity on response to anti-TNF therapy in moderate-to-severe plaque psoriasis: results of the PREDIR study.
    J Dermatolog Treat 2017 Mar 8:1-7. Epub 2017 Mar 8.
    c Immunology Unit , Instituto de Investigación Sanitaria del Hospital Universitario La Paz (IdiPAZ) , Madrid , Spain.
    Purpose: This study was conducted to examine the relationship between loss of clinical response to anti-tumor necrosis factor (TNF) therapy and the production of anti-drug antibodies (ADAs) and the potential effects of biologic immunogenicity.

    Materials And Methods: This observational, non-interventional, cross-sectional study included patients with moderate-to-severe plaque psoriasis and secondary failure of adalimumab, etanercept and infliximab who were seen in the clinical practice setting. Clinical data and blood samples were collected after patient enrollment at the time that next doses of anti-TNF therapy were scheduled. Read More

    Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry.
    J Eur Acad Dermatol Venereol 2017 Mar 8. Epub 2017 Mar 8.
    Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
    Background: While safety and efficacy of ustekinumab and secukinumab, monoclonal antibodies approved for psoriasis, are described in clinical trials, data on their real-life application are lacking.

    Objective: We compared the characteristics of patients initiating first-time treatment with secukinumab or ustekinumab.

    Methods: All Danish patients with moderate-to-severe plaque psoriasis treated with biologics are recorded in the nationwide DERMBIO registry. Read More

    The impact of topical Saint John's Wort (Hypericum perforatum) treatment on tissue tumor necrosis factor-alpha levels in plaque-type psoriasis: A pilot study.
    J Postgrad Med 2017 Mar 3. Epub 2017 Mar 3.
    Department of Clinical Pharmacy, Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, Iran.
    Context: Psoriasis is an inflammatory disorder, formed by inappropriate interaction of T lymphocytes with keratinocytes, and consequent eruption of immune responses. High concentrations of tumor necrosis factor-alpha (TNFα) are found in the skin lesions and plasma of patients with psoriasis. Hypericum perforatum, a phytomedicine that has both anti-inflammatory and antiproliferative properties, has been recently reported to be clinically helpful for improvement of psoriatic lesions. Read More

    Tildrakizumab for treating psoriasis.
    Expert Opin Biol Ther 2017 May 17;17(5):645-657. Epub 2017 Mar 17.
    a Department of Dermatology , University of Rome "Tor Vergata," , Rome , Italy.
    Introduction: Agents that block inflammatory pathways other than tumor necrosis factor (TNF) have represented new options for treating psoriasis in recent years. IL-23 is involved in regulating Th17 cells and is a potent activator of keratinocyte proliferation. Targeting IL-23p19 alone may be a promising treatment approach in patients with moderate-to-severe chronic plaque psoriasis, with a downregulation of Th17 and Th22 cell responses, while IL-12 blockade is not required to achieve efficacy in these patients. Read More

    Mechanistic rationales for targeting interleukin-17A in spondyloarthritis.
    Arthritis Res Ther 2017 Mar 8;19(1):51. Epub 2017 Mar 8.
    VA Medical Center Sacramento, Division of Rheumatology & Immunology, Sacramento, CA, USA.
    The term spondyloarthritis (SpA) is used to describe a group of inflammatory autoimmune diseases, including ankylosing spondylitis and psoriatic arthritis, with common genetic risk factors and clinical features. SpA is clinically distinct from rheumatoid arthritis and typically affects the spine, sacroiliac joints, entheses, and, less commonly, peripheral joints. Although the pathogenesis of SpA is not fully understood, recent findings have identified the interleukin (IL)-17 pathway as a key mediator of disease pathogenesis. Read More

    Patterns of clinical nail appearances in patients with cutaneous psoriasis.
    Clujul Med 2017 15;90(1):22-27. Epub 2017 Jan 15.
    Dermatology Department, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
    Background And Aim: Nail manifestations are often an overlooked aspect in psoriatic disease, cutaneous and joint involvement being far more often reported and investigated. The reported prevalence of nail changes varies in literature, specific fingernail clinical features having different degrees of occurrence. The aim of this study was to describe specific clinical patterns of fingernail alterations in adult patients with plaque-type psoriasis in a university hospital in the North-West of Romania. Read More

    Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.
    J Eur Acad Dermatol Venereol 2017 Feb 27. Epub 2017 Feb 27.
    Department of Medicine, Section of Dermatology and Venereology, University of Verona, Verona, Italy.
    Psoriasis is a common disease, which has a considerable impact on the healthcare system. Therefore, appropriate use of therapeutic resources is very important. Management of psoriasis in daily clinical practice is highly variable because many issues are still debated and not definitely addressed by the evidence-based medicine. Read More

    Psoriasis in Children and Adolescents: Epidemiological Study of 280 Patients from Mexico.
    Rev Invest Clin 2017 Jan-Feb;69(1):47-50
    UMAE Hospital de Pediatría, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jal, Mexico.
    Background: Psoriasis in children and adolescents has not been well studied in Mexico.

    Objective: To study the epidemiological characteristics of psoriasis in this age group.

    Methods: This is a retrospective study in an academic, tertiary care dermatology center from January 1999 to December 2014. Read More

    Molecular signatures order the potency of topically applied anti-inflammatory drugs in patients with atopic dermatitis.
    J Allergy Clin Immunol 2017 Feb 24. Epub 2017 Feb 24.
    Innovaderm Research, Montreal, Quebec, Canada.
    Background: Atopic dermatitis (AD) presents a large unmet need for treatments with better safety and efficacy. To facilitate development of topical therapeutics, we need an efficient model for assessing different formulations and concentrations. The "plaque model" has been successfully implemented in patients with psoriasis, another common inflammatory disease, to assess the efficacy of topical treatments. Read More

    The role of intradermal proliferation of T-cells in the pathogenesis of psoriasis.
    An Bras Dermatol 2017 Jan-Feb;92(1):41-44
    N.N Petrov Institute of Oncology - St.-Petersburg, Russia.
    Background:: Psoriasis is a common immune-mediated chronic inflammatory disease of the skin and joints, affecting 1-3% of the population. It is generally accepted that the pathogenesis of psoriasis involves accumulation of effector T-cells within lymph nodes and their subsequent migration into the skin through the blood system. Here we provide evidence that psoriatic plaque itself may serve as a source of inflammatory T-cells. Read More

    The Advantage of Cyclosporine A and Methotrexate Rotational Therapy in Long-Term Systemic Treatment for Chronic Plaque Psoriasis in a Real World Practice.
    Ann Dermatol 2017 Feb 3;29(1):55-60. Epub 2017 Feb 3.
    Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
    Background: Psoriasis is a chronic inflammatory disease. In the treatment of psoriasis, cyclosporine is commonly prescribed systemic agents. However, long-term use of cyclosporine is not recommended because of side effects such as nephrotoxicity or hypertension. Read More

    Secukinumab efficacy and safety in indian patients with moderate-to-severe plaque psoriasis: Sub-analysis from FIXTURE, a randomized, placebo-controlled, phase 3 study.
    Indian Dermatol Online J 2017 Jan-Feb;8(1):16-24
    Department of Dermatology, Novartis India Limited, Mumbai, Maharashtra, India.
    Title: Secukinumab efficacy and safety in Indian patients with moderate-to-severe plaque psoriasis: sub-analysis from FIXTURE (Full Year Investigative Examination of Secukinumab vs. Etanercept Using Two Dosing Regimens to Determine Efficacy in Psoriasis), a randomized, placebo-controlled, phase 3 study.

    Background: Evidence has suggested Interleukin (IL)-17A to be an important effector cytokine in the pathogenesis of psoriasis. Read More

    1 OF 67